Total votes: 5

Cash & Cash Equivalents: approx. $15M at Dec 31st 2011

Snapshot of technology and business:
Universal Biosensors, Inc. (Universal Biosensors) is a medical diagnostics company focused on the development, manufacture and commercialization of in vitro diagnostic test devices for point-of-care use. The company has signed a blood glucose diagnostic product agreements with LifeScan, Inc. which is a a Johnson & Johnson company. 

The company also has an agreement with Siemens for the Coagulation market (PT/NR).

The company is prediucting approx. A$25m UBI revenue forecast in the 12 months from regulatory approval (2010).

The diagnostic blood test devices it is developing consists a disposable test strip and a reusable meter. Each of the tests Universal Biosensors has developed, or is developing, utilize an electrochemical cell at the end of the test strip. The technology has a range of point-of-care blood tests in development, including a C-reactive protein test, D-dimer test and prothrombin time test (anticoagulation related products).

Institutional Investors:
The compnay has received revenue from operations as well as funding from Venture Capital, inclduing tier 1 Australian VCs CM capital.

Key People:
Mark Morrison is the CEO and has USA bsuiness experience, experience with AGEN and a former role in a VC firm. Other key members of the Board of Directors include Denis Hanley (Memtec & Baxter) and also Chairman Andrew Denver (formerly Pall Corporation).